Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap2
Naturally attenuated candidates
Next steps
- 1 Vaccine
- 1B Delivery route
Naturally attenuated candidates
Research Question
- Develop safe live virus Influenza vaccines – without risk of reassortment.
- Amenable for mass vaccination – control
Research Gaps and Challenges
- Develop vaccines easy to administer that induce strong mucosal immunity able to block shedding, and prevent infection and transmission of LPAIV and HPAIV
- Regulatory issues regarding attenuated vaccine usage due to safety for public health (possible reversion of virulence)
- Risk of reversion to virulence and/or recombination
- Application may depend on target species swine, equine versus avian species
- Cost of vaccine for each species
Solution Routes
- Solution for blocking reversion of virulence and reassortment
State Of the Art
- No incentive for industry to invest in research on Al attenuated vaccines as current regulation do not allow its use
Projects
What activities are planned or underway?
US-UK Collab: Avian influenza virus in cattle, a framework for forecasting transmission dynamics of zoonotic disease in livestock systems
Planned Completion date 31/01/2030
Source Countries:
United States
PARTNERSHIP:Harnessing Bovine Organoids to Advance HPAI Influenza A Virus Research
Planned Completion date 14/03/2029
Source Countries:
United States